Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. to recover losses incurred by shareholders due to alleged securities fraud between February 23, 2022, and July 30, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit alleges that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is claimed that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were allegedly materially false and misleading [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders [5]. - The firm has been ranked among the top securities litigation firms in the United States for seven consecutive years [5].
Baxter International, Inc. (BAX) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 15, 2025 Deadline